Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Gains from Investment Securities (2022 - 2025)

Praxis Precision Medicines (PRAX) has 4 years of Gains from Investment Securities data on record, last reported at $819000.0 in Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 642.38% year-over-year to $819000.0; the TTM value through Dec 2025 reached $2.1 million, changed N/A, while the annual FY2025 figure was $2.1 million, N/A changed from the prior year.
  • Gains from Investment Securities reached $819000.0 in Q4 2025 per PRAX's latest filing, up from $52000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $1.2 million in Q1 2025 and bottomed at -$151000.0 in Q4 2024.
  • Average Gains from Investment Securities over 4 years is $155375.0, with a median of $14500.0 recorded in 2022.
  • Peak YoY movement for Gains from Investment Securities: plummeted 3120.0% in 2024, then skyrocketed 5100.0% in 2025.
  • A 4-year view of Gains from Investment Securities shows it stood at $7000.0 in 2022, then decreased by 28.57% to $5000.0 in 2023, then tumbled by 3120.0% to -$151000.0 in 2024, then soared by 642.38% to $819000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $819000.0 in Q4 2025, $52000.0 in Q3 2025, and $23000.0 in Q2 2025.